Patient populations affected with orphan diseases are rare and patient identification can be challenging and time-consuming.
Our pharmaceutical client, while anticipating likely FDA approval for its new gene therapy, faced significant challenges identifying affected patients and encouraging the adoption of genetic testing into community physician practices.
Learn how the InformedACCESSTM solution we deployed with our client resulted in highly successful patient identification – ensuring that following FDA approval, more than 1,000 patients over a period of 18 months received post-test genetic counseling and test interpretation from InformedDNA’s board-certified genetic counselors.
InformedDNA is the authority on the appropriate use of genetic testing. We leverage the country’s largest full-time staff of lab-independent, board-certified genetics specialists to ensure access to the highest quality genetics expertise and services. Key offerings for pharmaceutical and biotech companies include support for clinical trial design, patient identification, and recruitment; patient and physician engagement; clinical genetic counseling; and, test ordering and interpretations services.
If you have questions or would like to chat, email us at pharma@InformedDNA.com; or, call us at 844-846-3763.
Download your copy of this case study now.
[hubspot type=form portal=5192453 id=e06018d4-69fa-4bf7-ad3a-a9a4958bd293]
